Skip to Content

Viemed in 'strong position'

Viemed in 'strong position'

Casey HoytLAFAYETTE, La. – Viemed Healthcare reported net revenue of $37.5 million for the fourth quarter, a 30% increase over the same quarter in 2021, and $138.8 million for full year 2022. 

Net income for the quarter and year totaled $2.4 million and $6.2 million, respectively. Adjusted EBITDA totaled approximately $9.3 million and $30 million, respectively. 

“Our favorable resolution of the OIG matter, debt free balance sheet and access to $90 million of additional liquidity through new credit facilities have us in an incredibly strong position to capitalize on the positive trends in our industry," said Casey Hoyt, CEO. "The health care market and regulatory environment are stabilizing, and we are at an inflection point of opportunity for both organic and inorganic growth. I'm extraordinarily proud of the current state of our organization and very excited about upcoming opportunities to treat a rapidly expanding patient base.” 

Viemed expects to generate net revenues attributable to its core business of about $38 million to $39 million during the first quarter of 2023. 

Additionally, on March 6, 2023, at 9:15 a.m. ET, representatives from Viemed will be at the Nasdaq MarketSite in Times Square while Hoyt rings the Opening Bell. A live stream will be available at:


To comment on this post, please log in to your account or set up an account now.